Recently, CAR T cells targeting BCMA have been approved by the FDA for the treatment of relapsed or refractory MM under the brand name Abecma (Idecabtagene vicleucel) from Celgene after the pivotal phase II KarMMa trial demonstrated substantial efficacy (NCT03361748) [9]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.